Preclinical three-dimensional colorectal cancer model: The next generation of in vitro drug efficacy evaluation

33Citations
Citations of this article
75Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Colorectal cancer (CRC), the third most common cancer diagnosed in both men and women in the United States, shows a highly ineffective therapeutic management. In these years neither substantial improvements nor new therapeutic approaches have been provided to patients. Performing the early lead discovery phases of new cancer drugs in cellular models, resembling as far as possible the real in vivo tumor environment, may be more effective in predicting their future success in the later clinical phases. In this review, we critically describe the most representative bioengineered models for anticancer drug screening in CRC from the conventional two-dimensional models to the new-generation three-dimensional scaffold-based ones. The scaffold aims to replace the extracellular matrix, thus influencing the biomechanical, biochemical, and biological properties of cells and tissues. In this scenario, we believe that reconstitution of tumor condition is mandatory for an alternative in vitro methods to study cancer development and therapeutic strategies.

Cite

CITATION STYLE

APA

Sensi, F., D’Angelo, E., D’Aronco, S., Molinaro, R., & Agostini, M. (2018, January 1). Preclinical three-dimensional colorectal cancer model: The next generation of in vitro drug efficacy evaluation. Journal of Cellular Physiology. Wiley-Liss Inc. https://doi.org/10.1002/jcp.26812

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free